Italia markets closed

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,0200+0,6100 (+25,31%)
Alla chiusura: 04:00PM EDT
3,2700 +0,25 (+8,28%)
Dopo ore: 07:45PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,4100
Aperto2,4600
Denaro3,0500 x 1000
Lettera3,2700 x 1400
Min-Max giorno2,4600 - 3,6000
Intervallo di 52 settimane1,4500 - 13,7700
Volume5.599.223
Media Volume251.545
Capitalizzazione76,599M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-2,0050
Prossima data utili14 nov 2022 - 18 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A4,50
  • GlobeNewswire

    Terns Announces $65 Million Oversubscribed Offering

    FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that it has agreed to sell, by way of an underwritten public offering, 12,250,000 shares of its common stock at a price of $2.42 per share and, to certain i

  • GlobeNewswire

    Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

    TERN-701 (allosteric BCR-ABL inhibitor) advances into Phase 1 trial for CML in ChinaIND-enabling activities for TERN-601 (GLP-1R agonist) remain on track; Phase 1 obesity trial initiation expected in 2023Initiated dosing of TERN-501 (THR-β agonist) Phase 2a DUET combo clinical trial for NASH; top-line data expected in second half of 2023Cash and equivalents of $140 million provides runway into 2025, supporting three expected clinical trial readouts across three product candidates and three indic

  • GlobeNewswire

    Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

    FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced the appointment of Radhika Tripuraneni, M.D., M.P.H. to the Company’s Board of Directors. Dr. Tripuraneni serves as the Chief Development Officer of Prothena Cor